NASDAQ | TSX: ACB
Canada's
Leading Medical Cannabis Company and MedReleaf Australia
Launch Innovative Resin Cartridges to Offer Greater Choice for
Patients
EDMONTON, AB, June 5, 2024
/PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX:
ACB) – the Canadian based leading global medical cannabis
company, in conjunction with MedReleaf Australia, is excited to
announce the launch of its premium 1.2g resin cartridges in
Australia. This expansion marks a
significant step in Aurora's mission to provide high-quality
products to patients worldwide. Now available for doctors to
prescribe to patients in Australia, Aurora's new resign cartridges,
developed and manufactured at the company's EU-GMP and TGA-GMP
certified facility, will be distributed by MedReleaf Australia.
"We are thrilled to bring premium resin cartridges to the
Australian market, a signal of our commitment to expanding patient
access to an even greater variety of premium cannabis," said
Kristin Viccars, Interim Managing
Director, MedReleaf Australia. "Our products are designed with the
highest standards of quality with safety in mind, and we are
confident that Australian patients will value the unique experience
our cartridges offer. We continue to look at new opportunities to
expand our portfolio and patient care."
The new resin cartridges include offerings from Aurora and
IndiMed. The IndiMed brand offering focuses on providing affordable
medicine and improving access for patients. The Aurora brand
offering features cultivar specific options such as Sourdough and
Electric Honeydew, Aurora's leading proprietary cultivars. All
products are full spectrum, ensuring a comprehensive cannabinoid
profile for a more effective and balanced experience. These resin
cartridges represent a significant advancement for MedReleaf
Australia as it continues to expand its product line up in the
market. The new resign cartridges are available as of
June 4, 2024.
Key features of Aurora and Indimed's resin cartridges
include:
- Exceptional Flavour Profiles: Using high-quality
terpenes and pure extracts to deliver rich and authentic
flavours.
- High Potency: Ensures a powerful and consistent
experience with each use.
- Safety and Quality: Manufactured in
state-of-the-art facilities, adhering to strict TGA-GMP quality
control and safety standards.
- User-Friendly Design: Easy to use, making it a
convenient choice for all patients.
For additional information doctors and health care professionals
can contact MedReleaf Australia's clinical support team or visit
their website: www.medreleafaustralia.com.au.
About Aurora Cannabis
Aurora is opening the world to cannabis, serving both the
medical and consumer markets
across Canada, Europe, Australia and South
America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global
cannabis, dedicated to helping people improve their lives. The
Company's adult- use brand portfolio includes Aurora Drift, San
Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical
cannabis brands include MedReleaf, CanniMed, Aurora and Whistler
Medical Marijuana Co, as well as international brands, Pedanios,
Bidiol, IndiMed and CraftPlant. Aurora also has a controlling
interest in Bevo Farms Ltd., North America's leading
supplier of propagated agricultural plants. Driven by science and
innovation, and with a focus on high-quality cannabis products,
Aurora's brands continue to break through as industry leaders in
the medical, wellness and adult recreational markets wherever they
are launched. Learn more at www.auroramj.com and follow
us on X and LinkedIn.
Aurora's Common Shares trade on the NASDAQ and TSX under the
symbol "ACB".
About MedReleaf Australia:
MedReleaf Australia is a subsidiary of Aurora Cannabis Inc.,
established in 2016. MedReleaf is licensed by the Australian
Federal Government's Office of Drug Control (ODC) to cultivate and
manufacture medical cannabis. MedReleaf also has licenses to
import, export and wholesale medical cannabis. Its wholly owned
subsidiary in New Zealand also has
a Medicinal Cannabis Supply Licence issued by the New Zealand
Ministry of Health. MedReleaf Australia is backed by more than 50
combined years of pharmaceutical and healthcare expertise, is
driven by Research and Development. An asset-lean distinct business
positioned to take advantage of a rapidly growing market, built to
service the Australian and New
Zealand medical industries including doctors, pharmacists,
and patients.
Forward Looking Information
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements").
Forward-looking statements are frequently characterized by words
such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain
events or conditions "may" or "will" occur. Forward-looking
statements made in this news release include, but are not limited
to, statements regarding the launch and availability of the
Company's premium resin cartridges in the Australian market and
future product expansion opportunities in that market and
globally.
These forward-looking statements are only predictions. Forward
looking information or statements contained in this news release
have been developed based on assumptions management considers to be
reasonable. Material factors or assumptions involved in developing
forward-looking statements include, without limitation, publicly
available information from governmental sources as well as from
market research and industry analysis and on assumptions based on
data and knowledge of this industry which the Company believes to
be reasonable. Forward-looking statements are subject to a variety
of risks, uncertainties and other factors that management believes
to be relevant and reasonable in the circumstances could cause
actual events, results, level of activity, performance, prospects,
opportunities or achievements to differ materially from those
projected in the forward-looking statements. These risks include,
but are not limited to, the ability to retain key personnel, the
ability to continue investing in infrastructure to support growth,
the ability to obtain financing on acceptable terms, the continued
quality of our products, customer experience and retention, the
development of third party government and non-government consumer
sales channels, management's estimates of consumer demand in
Canada and in jurisdictions where
the Company exports, expectations of future results and expenses,
the risk of successful integration of acquired business and
operations (with respect to the Transaction and more generally with
respect to future acquisitions), management's estimation that
SG&A will grow only in proportion of revenue growth, the
ability to expand and maintain distribution capabilities, the
impact of competition, the general impact of financial market
conditions, the yield from cannabis growing operations, product
demand, changes in prices of required commodities, competition, and
the possibility for changes in laws, rules, and regulations in the
industry, epidemics, pandemics or other public health crises,
including the current outbreak of COVID-19, and other risks,
uncertainties and factors set out under the heading "Risk Factors"
in the Company's annual information from dated June 14, 2023 (the "AIF") and filed with Canadian
securities regulators available on the Company's issuer profile on
SEDAR+ at www.sedarplus.com and filed with and available on
the SEC's website at www.sec.gov. The Company cautions that the
list of risks, uncertainties and other factors described in the AIF
is not exhaustive and other factors could also adversely affect its
results. Readers are urged to consider the risks, uncertainties and
assumptions carefully in evaluating the forward-looking statements
and are cautioned not to place undue reliance on such information.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable securities
law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aurora-unveils-premium-resin-cartridges-in-australia-302164190.html
SOURCE Aurora Cannabis Inc.